newsfilter
← Latest News
GlobeNewswire·

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RNXT
  • RenovoRx announced online publication of a pharmacokinetic & pharmacodynamic sub-study from its Phase III TIGeR-PaC clinical trial regarding the TAMP platform for targeted intra-arterial gemcitabine delivery via RenovoCath.
  • The sub-study evaluated IAG (intra-arterial gemcitabine) versus IV gemcitabine in locally advanced pancreatic cancer using data from 16 patients across six trial sites.
  • Results demonstrated a direct correlation between increased inactive metabolite levels & reduced CA 19-9 biomarkers following IAG administration.
  • The TAMP delivery approach potentially increases local drug potency while reducing systemic exposure & common side effects by limiting circulating gemcitabine levels.
  • Dr. Reza Nazemzadeh noted the approach may enhance efficacy while minimizing toxicity to improve patient tolerability.
  • The abstract was published online on May 21, 2026, for presentation at the 2026 ASCO Annual Meeting held May 29 – June 2, 2026, in Chicago.
  • RenovoRx reported $1.1 million in RenovoCath sales for the full year 2025 & $563,000 in sales for the first quarter of 2026.
  • The company anticipates full enrollment in the TIGeR-PaC trial in June 2026 with final data readout expected in mid-to-late 2027.
  • IAG utilizes the FDA-cleared RenovoCath device & has received Orphan Drug Designation for pancreatic cancer & bile duct cancer.
  • IAG is under investigation via an FDA investigational new drug application & has not received approval for commercial sale.